We believe this site might serve you best:

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

RNasin® Ribonuclease Inhibitor, Recombinant Product Information

Instructions for Use of Product(s)
N2511, N2515
Literature # 9PIN251

RNasin® Ribonuclease Inhibitor has broad-spectrum RNase inhibitory properties. The 50kDa protein exerts its inhibitory effect by noncovalently binding to RNases at a 1:1 ratio. The Ki value for the binding of RNasin® Ribonuclease Inhibitor to RNase (e.g., RNase A) is approximately 10–14M. Promega offers two different preparations: Natural RNasin® Ribonuclease Inhibitor (Cat.# N2111) and Recombinant RNasin® Ribonuclease Inhibitor (Cat.# N2511, N2515). All of these products are purified using a combination of ion exchange and affinity chromatography, and Natural and Recombinant RNasin® Ribonuclease Inhibitors are devoid of DNA exonuclease and endonuclease activity and RNase activity. In addition to its ability to inhibit RNase activity, RNasin® Ribonuclease Inhibitor has been shown to inhibit angiogenesis induced by angiogenin, basic fibroblast growth factor (bFGF) and sodium orthovanadate. Moreover, RNasin® Ribonuclease Inhibitor reduced neovascularization evoked by implanted tumor cells and significantly inhibited tumor growth in a murine model.

Printed in USA. Revised 9/16

Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom